Table 9.

Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) vs. other diseases (inflammatory and non-inflammatory) of the CNS (INF and N-INF) based on the identified protein spots

	Classification resultsb,c
	Disease	Predicted Group Membership		Total
		RRMS	INF and N-INF
Original
Count	RRMS	57	12	69
	INF and N-INF	11	58	69
%	RRMS	82.6	17.4	100
	INF	15.9	84.1	100
Cross-validateda
Count	RRMS	56	13	69
	INF and N-INF	11	58	69
%	RRMS	81.2	18.8	100
	INF & N-INF	15.9	84.1	100

^aCross validation is done only for those cases in the analysis. In cross validation, each sample is classified by the functions derived from all samples other than the one under analysis

^b83.3% of original grouped cases correctly classified

^c82.6% of cross-validated grouped cases correctly classified